Gut

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Published Online First: 16 March 2006. doi:10.1136/gut.2005.076778
Gut 2006;55:1606-1616
Copyright © 2006 BMJ Publishing Group Ltd & British Society of Gastroenterology

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
gut.2005.076778v1
55/11/1606    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ebrahimkhani, M R
Right arrow Articles by Dehpour, A R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ebrahimkhani, M R
Right arrow Articles by Dehpour, A R
Topic Collections
Right arrowRelevant Article

LIVER

Naltrexone, an opioid receptor antagonist, attenuates liver fibrosis in bile duct ligated rats

M R Ebrahimkhani1, S Kiani2, F Oakley3, T Kendall3, A Shariftabrizi2, S M Tavangar4, L Moezi2, S Payabvash2, A Karoon2, H Hoseininik2, D A Mann3, K P Moore5, A R Mani5, A R Dehpour2

1 Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran, and the UCL Institute of Hepatology, Department of Medicine, Royal Free and University College Medical School, University College London, London, UK
2 Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
3 Liver Group, Southampton General Hospital, University of Southampton, Southampton, UK
4 Department of Pathology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
5 The UCL Institute of Hepatology, Department of Medicine, Royal Free and University College Medical School, University College London, London, UK

Correspondence to:
Correspondence to:
Professor K P Moore
The UCL Institute of Hepatology, Department of Medicine, Royal Free and University College Medical School, University College London, Rowland Hill St, London NW3 2PF, UK; kmoore{at}medsch.ucl.ac.uk

Aim: The aim of this study was to investigate the hypothesis that the opioid system is involved in the development of hepatic fibrosis.

Methods: The effect of naltrexone (an opioid receptor antagonist) on hepatic fibrosis in bile duct ligated (BDL) or sham rats was assessed by histology and hepatic hydroxyproline levels. Liver matrix metalloproteinase 2 (MMP-2) was measured by zymography, and {alpha} smooth muscle actin ({alpha}-SMA) and CD45 (leucocyte common antigen) by immunohistochemistry. The redox state of the liver was assessed by hepatic glutathione (GSH)/oxidised glutathione (GSSG) and S-nitrosothiol levels. Subtypes of opioid receptors in cultured hepatic stellate cells (HSCs) were characterised by reverse transcriptase-polymerase chain reaction, and the effects of selective {delta} opioid receptor agonists on cellular proliferation, tissue inhibitor of metalloproteinase 1 (TIMP-1), and procollagen I expression in HSCs determined.

Results: Naltrexone markedly attenuated the development of hepatic fibrosis as well as MMP-2 activity (p<0.01), and decreased the number of activated HSCs in BDL rats (p<0.05). The development of biliary cirrhosis altered the redox state with a decreased hepatic GSH/GSSG ratio and increased concentrations of hepatic S-nitrosothiols, which were partially or completely normalised by treatment with naltrexone, respectively. Activated rat HSCs exhibited expression of {delta}1 receptors, with increased procollagen I expression, and increased TIMP-1 expression in response to {delta}1 and {delta}2 agonists, respectively.

Conclusions: This is the first study to demonstrate that administration of an opioid antagonist prevents the development of hepatic fibrosis in cirrhosis. Opioids can influence liver fibrogenesis directly via the effect on HSCs and regulation of the redox sensitive mechanisms in the liver.


Abbreviations: BDL, bile duct ligated; MMP, matrix metalloproteinase; {alpha}-SMA, {alpha} smooth muscle actin; GSH, glutathione; GSSG, oxidised glutathione; HSC, hepatic stellate cell; RT-PCR, reverse transcriptase-polymerase chain reaction; TIMP, tissue inhibitor of metalloproteinase; SDS, sodium dodecyl sulphate; NO, nitric oxide; ALP, alkaline phosphatase; ALT, alanine aminotransferase; PDGF, platelet derived growth factor; ct, cycle threshold; HCV, hepatitis C virus

Keywords: liver fibrosis; opioids; glutathione; tissue inhibitor of metalloproteinase; hepatic stellate cells; cirrhosis


Relevant Article

Digest
Robin Spiller and Alastair Watson
Gut 2006 55: 1529a. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
Physiol. Rev.Home page
S. L. Friedman
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
Physiol Rev, January 1, 2008; 88(1): 125 - 172.
[Abstract] [Full Text] [PDF]


Home page
GutHome page
D. Chakass, D. Philippe, E. Erdual, S. Dharancy, M. Malapel, C. Dubuquoy, X. Thuru, J. Gay, C. Gaveriaux-Ruff, P. Dubus, et al.
{micro}-Opioid receptor activation prevents acute hepatic inflammation and cell death
Gut, July 1, 2007; 56(7): 974 - 981.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2006 BMJ Publishing Group Ltd & British Society of Gastroenterology